Influenza Archives - The Native Antigen Company

Mar 29, 2023Influenza

HITTING A MOVING TARGET

By Holge Hannemann, Director of Research, The Native Antigen Company Influenza viruses A and B are a major public health concern, mainly affecting the pharynx, trachea, and sometimes the lungs of millions of people worldwide each year, with symptoms that range from...

Feb 14, 2023Influenza

Influenza antigens for Northern Hemisphere’s 2023-2024 flu season

Most recent figures published by UK Health Security Agency show that the 2022/2023 Influenza season has been worse than any of the past surveillance periods (GOV.UK, 2023), see Figure 1 (below). High level of Influenza incidence increased the burden on the National...

Nov 18, 2022Influenza

The Native Antigen Company introduces new range of influenza antigens

Season-specific Haemagglutinin and Neuraminidase antigens will support vaccine and diagnostic reformulation programmes New range developed to cover 2023 southern hemisphere flu season Oxford, UK, 14 November 2022: The Native Antigen Company (part of LGC Clinical...

Aug 17, 2020Disease insight, Immunoassays, Influenza, Services, Vaccines

The Yearly Race for an Influenza Vaccine and the Role of Reagents

In this blog, we explain how seasonal and pandemic influenza vaccines are developed, manufactured and validated, and introduce our contract services for the rapid development of custom influenza reagents. The Influenza Viruses: A Quick Recap The influenza viruses are...

HITTING A MOVING TARGET

Influenza antigens for Northern Hemisphere’s 2023-2024 flu season

The Native Antigen Company introduces new range of influenza antigens

The Yearly Race for an Influenza Vaccine and the Role of Reagents

Recent Posts

Archives

Categories